Based on the pathogenesis of PAP, several new therapeutic approaches for treating autoimmune PAP targeting GM-CSF are in clinical trials, including plasmapheresis [128], GM-CSF administration [129, 130], and rituximab [131, 132]. Here, CSF2 is linked to autoimmune pulmonary alveolar proteinosis.